Press Releases

Avance Clinical, the Australian and North American market-leading CRO for biotechs, was asked to present their GlobalReady drug development solution to more than 45 Korean biotechs and pharmaceutical companies in Seoul, Korea last week as part of a special symposium at KoNECT Korea Conference. Avance Clinical’s Korean CRO partner Dt & SanoMedics initiated the Global Clinical Trial Strategy Symposium and invited Avance Clinical to co-host. The Avance Clinical team

SOPHiA GENETICS, a category-defining software company and a global leader in data-driven medicine today announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK), a top cancer treatment and research institution, and AstraZeneca (LSE/STO/Nasdaq: AZN) to bring high quality, comprehensive cancer testing to a global scale. With this collaboration, the three leading organizations will further their shared goal to advance health equity on a global scale by providing inclusive acce

dsm-firmenich is proud to announce its strategic partnership with Bod Science, an Australian-based pioneer in medical cannabis. The collaboration follows promising preliminary findings from Bod Science’s Phase IIb clinical trial, demonstrating the efficacy of a cannabidiol (CBD) formulation in alleviating insomnia symptoms and will see dsm-firmenich’s high quality GMP CBD active pharmaceutical ingredient (API) play a crucial role in advancing the next phase of commercialization. B

BD (Becton, Dickinson and Company), a leading global medical technology company, is excited to showcase at CPhI Barcelona 2023 – building on its decades of expertise in partnering with the biopharmaceutical industry to advance drug delivery excellence. CPhI will be held in Barcelona, Spain from October 24 to October 26, 2023. The conference will focus on the latest pharmaceutical packaging innovations and drug delivery devices.  At the booth, BD will share our wide portfo

Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), announces additional investments as part of its long-term dedication to customer partnerships. Vetter’s extensive 40+ years of experience in aseptic filling and packaging shows a consistent desire for sustainable growth and corporate development. The pharmaceutical service provider plans with future-driven considerations to meet its long-lead goals for continued expansion and customer satisfaction.

Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”) today announced the successful completion of its 3rd engineering batch of BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 at its U.S. manufacturing site. NXC-201 will be manufactured for each individual patient using the patient’s own T cells at our state-of-the-art cellular immunotherapy manufacturing facility in California. “We be

Sirio Pharma Co., Ltd. a leading global CDMO, is pleased to announce the addition of new gummy manufacturing capabilities at its Best Formulations site, the company's manufacturing facility in the United States. Through the seamless integration of Best Formulations into Sirio’s global operations, the CDMO is now able to offer customers localized manufacturing capabilities across three continents. Best Formulations is on track to achieve full operational readiness by the en

PharmaKure, a pharmaceutical company spun out from the University of Manchester, announces successful study results for a novel whole blood test for quantifying Alzheimer’s Disease biomarkers. PharmaKure’s proprietary ALZmetrixTM blood test can identify blood-based biomarkers in patients with Alzheimer’s Disease to provide early warning of cognitive decline. The study was designed to focus on the testing of whole blood. A number of biomarkers were accessed for the

Coriolis Pharma, a global service provider and a world leader in the formulation research and development of (bio)pharmaceutical drugs, including cell and gene therapy products and vaccines, today announced an investment from funds managed by KKR, a leading global investment firm. In this context, Coriolis Pharma will enter into a strategic growth partnership with Frontier Biosolutions, a global pharma services platform newly formed by KKR and Flerie Invest AB. Michael and Thomas Wi

LEO Pharma A/S, a global leader in medical dermatology, today presented results from the DELTA 2 trial at the 32nd European Academy of Dermatology and Venereology (EADV) Congress in Berlin. DELTA 2 is the second of two pivotal phase 3 clinical trials with delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor for the potential treatment of adults with moderate to severe chronic hand eczema (CHE).1,4 DELTA 2 was a randomized, double-blind, cream vehicle-contr